Author Question: A pediatric client presents with tinea capitis. The nurse anticipates that the infection will be ... (Read 63 times)

charchew · **on:** Jul 23, 2018

A pediatric client presents with tinea capitis. The nurse anticipates that the infection will be treated with griseofulvin (Fulvicin) for 8 to 10 weeks at a dose of ______ mg/kg/day.

Standard Text: Record your answer rounding to the nearest whole number.
Fill in the blank with the appropriate word.

Question 2

A client has a serious systemic fungal infection. The nurse anticipates that the physician will prescribe which medications to treat this infection?

Standard Text: Select all that apply.
1. Amphotericin B (Fungizone)
2. Flucytosine (Ancobon)
3. Caspofungin (Cancidas)
4. Griseofulvin (Fulvicin)
5. Terbinafine (Lamisil)

KKcool · **Reply #1 on:** Jul 23, 2018

Answer to Question 1

Correct Answer: 10
Rationale: The typical regimen for griseofulvin (Fulvicin) is 10 mg/kg/day for 8 to 10 weeks.
Global Rationale: The typical regimen for griseofulvin (Fulvicin) is 10 mg/kg/day for 8 to 10 weeks.

Answer to Question 2

Correct Answer: 1,2,3
Rationale 1: Pharmacologic options for serious systemic mycoses are limited. Amphotericin B (Fungizone) has been the traditional drug of choice since the 1960s.
Rationale 2: Pharmacologic options for serious systemic mycoses are limited. Although rarely used as monotherapy, flucytosine (Ancobon) is sometimes used in combination with amphotericin B in the pharmacotherapy of severe Candida infections.
Rationale 3: Pharmacologic options for serious systemic mycoses are limited. Caspofungin (Cancidas) is a newer drug that is becoming an important alternative to amphotericin B in the treatment of aspergillosis.
Rationale 4: Griseofulvin is an oral therapy for tinea corporis, which is not considered a systemic fungal infection.
Rationale 5: Terbinafine is an oral therapy for tinea corporis which is not considered a systemic fungal infection.
Global Rationale: Pharmacologic options for serious systemic mycoses are limited. Amphotericin B (Fungizone) has been the traditional drug of choice for systemic fungal infections since the 1960s. Azole drugs such as itraconazole, however, are considerably safer and have become preferred drugs for less severe infections. Although rarely used as a monotherapy, flucytosine (Ancobon) is sometimes used in combination with amphotericin B in the pharmacotherapy of severe Candida infections. Caspofungin (Cancidas) is becoming an important alternative to amphotericin B in the treatment of aspergillosis. Griseofulvin and terbinafine are oral agents used as therapy for tinea corporis, which is not considered a systemic fungal infection.